Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder
- 18 February 2003
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 5 (6) , 472-482
- https://doi.org/10.1002/jgm.377
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutationsHuman Molecular Genetics, 2001
- Expression and Endocytosis of Lysosomal Aspartylglucosaminidase in Mouse Primary NeuronsJournal of Neuroscience, 1998
- Activation and Oligomerization of AspartylglucosaminidaseJournal of Biological Chemistry, 1998
- Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patientsHuman Molecular Genetics, 1998
- Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferaseThe EMBO Journal, 1997
- Uptake of α-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitroGene Therapy, 1997
- A mouse model for the human lysosomal disease aspartylglycosaminuriaNature Medicine, 1996
- Primary Folding of AspartylglucosaminidaseJournal of Biological Chemistry, 1996
- Correction of Deficient Enzyme Activity in a Lysosomal Storage Disease, Aspartylglucosaminuria, by Enzyme Replacement and Retroviral Gene TransferHuman Gene Therapy, 1995
- Intracellular Sorting of Aspartylglucosaminidase: The Role ofN-Linked Oligosaccharides and Evidence of Man-6-P-Independent Lysosomal TargetingDNA and Cell Biology, 1995